26101 Research Road
Lawrence K. Cohen, president and CEO
Founded in 1998, Zyomyx is developing and commercializing a protein biochip platform technology as an integrated analytical system. The protein profiling biochip will permit the highly parallel detection and quantification of proteins and is designed to accelerate target discovery and validation, with applications in pharmaceutical drug development.
Zyomyx’s core technology integrates protein biochemistry with advanced materials science, microfabrication and novel detection physics. The protein biochip, its lead product, will be able to perform high-throughput protein discovery, protein profiling, protein structure and activity analyses, as well as protein-protein and protein-small molecule interaction studies.
The company has research and development groups in surface material sciences, as well as in protein engineering, combinatorial biology, protein production and microassay development.
Supply and collaboration agreement to obtain access to antibody collection and to develop antibodies for use on Zyomyx’s high-density protein biochips: BD Biosciences, a division of Becton Dickinson & Co. Inc.
Strategic alliance and joint development agreement to develop scanning instrumentation for data acquisition and analysis of Zyomyx protein biochips and related products: Axon Instruments Inc.
License to phage display antibody technology to develop high-density protein biochips using specific human antibodies from proprietary human antibody library: Dyax Corp.
Other partners include Cambridge Antibody Technology Group plc, MDS Proteomics Inc. and Fujirebio Inc.